Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
76 participants
INTERVENTIONAL
2023-06-03
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Effect of Pyridoxine as Add-on Therapy with Standard Treatment in Obsessive Compulsive Disorder Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
Purpose of the study:
This study aims to examine the effect of Pyridoxine with standard treatment in Obsessive Compulsive Disorder patients.
Method:
It will be a prospective type of interventional study to to assess the effects of Pyridoxine along with standard treatment in OCD patients. The study will be conducted in the Department of Pharmacology,BSMMU and Department of Psychiatry, BSMMU, from September 2022 to July 2024. A total of 76 OCD patients will be selected according to inclusion and exclusion criteria. The patients will be divided randomly into 2 groups: group A and group B. Group A will consist of 38 patients who will receive tablet pyridoxine 25 mg twice daily with standard treatment and group B would consist of 38 patients who will receive placebo twice daily along with standard treatment for 8 weeks. To see the effects of pyridoxine, Yale-Brown score of obsessive-compulsive disorders (Y-OCD) would be assessed by Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at baseline (before pyridoxine administration) and 8 weeks after intervention(after pyridoxine administration). Biochemical parameters of oxidative stress markers such as plasma malondialdehyde (MDA), RBC glutathione (GSH) would be performed at baseline (before pyridoxine administration) and 8 weeks after intervention.
Ethical consideration:
The study will follow the principles of the Declaration of Helsinki and of the World Medical Assembly. Patients will be informed about the study in easy language and then informed consent will be taken. This study has no potential risk to the patients. Confidentiality will be strictly maintained.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Vitamin C Upon SSRI-treated OCD Patients
NCT03754647
Effect of a Family-Based CBT Self-Help Intervention for Adolescents With OCD
NCT06942494
Effect of N-acetylcysteine as Add on Therapy With SSRI in Moderate to Severe OCD Patients
NCT04904952
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04641143
Memantine Augmentation in Obsessive-Compulsive Disorder
NCT00264238
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aim: This proposed study is therefore an effort whether there is any role of Pyridoxine (vit B6) adjuncts with standard treatment produce better improvement than standard treatment alone in OCD patients. Method: This study will be a randomized, double-blind, placebo-controlled trial that will be conducted in the department of pharmacology, BSMMU in collaboration with the department of psychiatry, BSMMU, Dhaka from the day of approval by the IRB (Institutional Review Board) to July 2024. A total of 76 patients suffering from OCD will be selected according to inclusion and exclusion criteria. The diagnosis of patients suffering from OCD and the selection of drug and dosage would be performed by a senior professor of the psychiatry department. After completing the necessary formalities including informed consent of the patients, the patient would undergo a selected questionnaire Yale-Brown Obsessive Scale (Y-BOCS-10) to assess the severity of the disease. The patients would be randomly allocated into two arms: control and intervention. Patients in the intervention arm would consist of 38 patients who will receive standard treatment plus tab pyridoxine 25 mg twice daily for 8 weeks. On the other hand, the control arm would consist of 38 patients who will receive standard treatment plus a placebo for 8 weeks. The severity of symptoms will be assessed after 8 weeks follow-up. Biochemical parameters of oxidative stress markers (RBC glutathione, plasma MDA) will be measured at baseline and after 8 weeks.Along with the biochemical parameters, Yale-Brown score of obsessive-compulsive disorders (Y-OCD) would also be assessed by Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at baseline and after 8 weeks. The regularity of medicine intake will be ensured over the telephone and from the patient's compliance sheet. Statistical analysis will be obtained by SPSS (statistical package for social science) version 24. The calculated 'p' value may suggest the level of significance (significant at p\<0.05). Ethical consideration: After approval from IRB (Institutional Review Board) every eligible patient will be informed about the intervention and the study objectives. Patients will also be informed that they can participate or to withdraw at any time without compromising their medical care. Patient confidentiality will be strictly maintained. Patient's personal data regarding the name, age, sex, and other information will not be disclosed anywhere and will be used only for research purposes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard treatment with pyridoxine
This group will receive standard treatment with pyridoxine 25 mg twice daily for 8 weeks
Pyridoxine
pyridoxine (Vitamin B6) will be given as an anti oxidant.
Standard treatment with placebo
This group will receive standard treatment with placebo 25 mg twice daily for 8 weeks
Placebo
Placebo will be given in control group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pyridoxine
pyridoxine (Vitamin B6) will be given as an anti oxidant.
Placebo
Placebo will be given in control group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* OCD patients fulfills Diagnostic criteria of DSM-5 (Diagnostic and Statistical Manual of Mental Disorders,5th Edition)
Exclusion Criteria
* Prior exposure to pyridoxine within last 2 months
* Pregnant and lactating mother
* Patients unwilling to participate or unwilling to give written consent
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sumaiya Nousheen Pinki
MD, Resident
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sumaiya Nousheen
Dhaka, , Bangladesh
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BSMMU/2023/7593
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.